FDA rejections to raise drug development cost (Houston Chronicle)
Under growing scrutiny since Vioxx was pulled from the market, the FDA in recent months has rejected a slew of experimental drugs or delayed their approval and required more data.

FDA errs on side of caution in drug approvals (Minneapolis-St. Paul Star Tribune)
TRENTON, N.J. - Under growing scrutiny since the blockbuster painkiller Vioxx was pulled from the market, the Food and Drug Administration (FDA) in recent months has rejected a slew of experimental drugs or delayed their approval and required more data. Besides keeping drugs some patients might desperately need off the market, the rejections have battered drug company stock prices and are ...

Fewer Drug Approvals? Buy! (The Motley Fool)
Stricter standards at the FDA could create a Foolish opportunity.